Table 1.
Characteristics of the study cohort.
| N = 72 (%) | |
|---|---|
| Age | |
| <50 | 6 (8.3) |
| >50 | 66 (91.7) |
| BMI | |
| <25 | 25 (34.7) |
| >25 | 47 (65.3) |
| Histotype | |
| E | 62 (86.1) |
| I-DED | 8 (11.1) |
| S | 2 (2.8) |
| CS | 0 |
| CCC | 0 |
| ESMO risk | |
| Low risk | 14 (19.4) |
| Intermediate risk | 5 (6.9) |
| High-intermediate risk | 31 (43.1) |
| High risk | 22 (30.6) |
| Grading | |
| Low | 55 (76.4) |
| High | 17 (23.6) |
| FIGO stage | |
| IA | 45 (62.5) |
| IB–II | 13 (18.1) |
| III–IV | 14 (19.4) |
| LVI | |
| Absent | 25 (34.72) |
| Focal | 23 (31.94) |
| Massive | 23 (31.94) |
| Missing | 1 (1.39) |
| TCGA classification | |
| NSMP | 41 (56.9) |
| MSI | 31 (43.9) |
BMI, body mass index; E, endometrioid; I-DED, de-differentiated; S, serous; CS, carcinosarcoma; CCC, clear cell carcinoma; LVI, lymphovascular invasion.